A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

增熙 林; 榮楷 陳; 匡華 季; 上惠(Sang H. Yen) 顏; 世薰(Su S. Lo) 羅; 銘芳 吳; 偉修(Wei S. Hwang) 黃; 嘉康(Jacqueline Whang-Peng) 彭汪; 敏(M. Liu) 劉; 光耀(Kuang Y. Chen) 陳

doi:10.6316/TRO/199401(3)263

A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

貢獻的翻譯標題: Cisplatin, 5Fluorouracil，高劑量Leucovorinl在中國人頭頸部癌病之前導性研究

林增熙
, 陳榮楷
, 季匡華
, 顏上惠(Sang H. Yen)
, 羅世薰(Su S. Lo)
, 吳銘芳
, 黃偉修(Wei S. Hwang)
, 彭汪嘉康(Jacqueline Whang-Peng)
, 劉敏(M. Liu)
, 陳光耀(Kuang Y. Chen)

研究成果: 雜誌貢獻 › 文章 › 同行評審

摘要

Cisplatin、5-FU及高劑量leucovorin化療報導顯示對頭頸癌病患治療具高度療效。總體而言，毒性是高的。國內在考慮進行第三期的高劑量PFL化療研究之前，應先從事前期的PFL化療研究。研究方法：選定罹患美國癌症委員會(AJCC)第四期、且未曾接受治療之頭頸組織鱗片細胞癌的病患，施以每天每平方公尺體表面積混合之cisplatin 20毫克、5-FU 500毫克、leucovorin 500亳克，經連續靜脉滴注96小時，每28天為一療程，評估其治療反應、毒性反應。結果：共有14位病人進入此研究。達完全緩解者1位(7%)部分緩解者8位(57%) ，緩解率達64%。主要的毒性反應是口腔粘膜炎及白血球缺乏。其中口腔黏膜炎達第三、四度毒性反應之患者有35%。無治療相關之死亡發生。結論：雖然用高劑量PFL治療頭頸癌是有效的療法，但其毒性反應表現過度。建議在未來研究中以具有相同療效但毒性减少很多的其它PFL療法來作進一步的評估。

貢獻的翻譯標題	Cisplatin, 5Fluorouracil，高劑量Leucovorinl在中國人頭頸部癌病之前導性研究
原文	英語
頁（從 - 到）	263-268
頁數	6
期刊	放射治療與腫瘤學
卷	1
發行號	3
DOIs	https://doi.org/10.6316/TRO/199401(3)263
出版狀態	已發佈 - 1994
對外發佈	是

UN SDG

此研究成果有助於以下永續發展目標

SDG 3 良好的健康和福祉

Keywords

頭頸癌治療
5-FU
leucovorin
Cisplatin

存取文件

10.6316/TRO/199401(3)263

引用此

林增熙, 陳榮楷, 季匡華, 顏上惠(SangHY, 羅世薰(SuSL, 吳銘芳, 黃偉修(WeiSH, 彭汪嘉康(JacquelineW-P, 劉敏(ML & 陳光耀(KuangYC 1994, 'A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer', 放射治療與腫瘤學, 卷 1, 編號 3, 頁 263-268. https://doi.org/10.6316/TRO/199401(3)263

@article{dba34a11e4564597a3e3c0a5d5fa2a8b,

title = "A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer",

abstract = "Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary. Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m\textasciicircum{}2, 5-fluorouracil (5-FU) 800mg/m\textasciicircum{}2, leucovorin (LV) 500mg/m\textasciicircum{}2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity. Results: Fourteen patients were studied. There were 1 CR (7\%) and 8 PR (57\%) with a overall response rate (CR+PR) of 64\%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35\% of patients. No treatment related death occurred. Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.",

keywords = "Cisplatin, Leucovorin, 5-FU, head and neck cancer, 頭頸癌治療, 5-FU, leucovorin, Cisplatin",

author = "增熙林 and 榮楷陳 and 匡華季 and 顏, \{上惠(Sang H. Yen)\} and 羅, \{世薰(Su S. Lo)\} and 銘芳吳 and 黃, \{偉修(Wei S. Hwang)\} and 彭汪, \{嘉康(Jacqueline Whang-Peng)\} and 劉, \{敏(M. Liu)\} and 陳, \{光耀(Kuang Y. Chen)\}",

year = "1994",

doi = "10.6316/TRO/199401(3)263",

language = "English",

volume = "1",

pages = "263--268",

journal = "放射治療與腫瘤學",

issn = "1023-988x",

publisher = "台灣放射腫瘤學會",

number = "3",

}

TY - JOUR

T1 - A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

AU - 林, 增熙

AU - 陳, 榮楷

AU - 季, 匡華

AU - 顏, 上惠(Sang H. Yen)

AU - 羅, 世薰(Su S. Lo)

AU - 吳, 銘芳

AU - 黃, 偉修(Wei S. Hwang)

AU - 彭汪, 嘉康(Jacqueline Whang-Peng)

AU - 劉, 敏(M. Liu)

AU - 陳, 光耀(Kuang Y. Chen)

PY - 1994

Y1 - 1994

N2 - Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary. Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity. Results: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred. Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.

AB - Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary. Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity. Results: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred. Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.

KW - Cisplatin

KW - Leucovorin

KW - 5-FU

KW - head and neck cancer

KW - 頭頸癌治療

KW - 5-FU

KW - leucovorin

KW - Cisplatin

U2 - 10.6316/TRO/199401(3)263

DO - 10.6316/TRO/199401(3)263

M3 - Article

SN - 1023-988x

VL - 1

SP - 263

EP - 268

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

IS - 3

ER -

A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

摘要

UN SDG

Keywords

存取文件

指紋

引用此